Evidence map›Paper›PMID 42450144›Full record

ArticleInternational journal of molecular sciences2026

Tritosomes-Digestion for LC-MS Conjugated Payloads Quantitation: A Universal Approach for Dual-Payloads ADCs.

Francesco Molinaro, Gabriele Sergio Colangelo, Patrizia Cocco, Andrea Di Ianni, Diana Knapp-Buehle, Andrea Paoletti, Elisa Bertotti, Kyra Cowan, Federico Riccardi Sirtori, Luca Barbero

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesco MolinaroInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.ORCID 0000-0002-8316-9447
Gabriele Sergio ColangeloInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.
Patrizia CoccoInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.
Andrea Di IanniInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.ORCID 0000-0002-3424-0585
Diana Knapp-BuehleNew Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Andrea PaolettiInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.
Elisa BertottiInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.
Kyra CowanNew Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Federico Riccardi SirtoriInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.ORCID 0000-0003-0319-4966
Luca BarberoInnovative Bioanalytics, New Biological Entities, Drug Metabolism and Pharmacokinetics (NBE-DMPK), Research and Development, Merck Healthcare KGaA, RBM S.p.A.-Istituto di Ricerche Biomediche "A. Marxer", an Affiliate of Merck KGaA, Via Ribes 1, 10010 Colleretto Giacosa, TO, Italy.ORCID 0000-0003-1125-2599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioanalytical methods to quantitate conjugated payloads are essential for assessing antibody-drug conjugate (ADC) stability and pharmacokinetics (PK). Dual-payload ADCs present analytical challenges; different linker chemistries can require complex digestion conditions to perform the cleavage. Developing separate methods for each linker combination can be time and resource demanding. Rat tritosomes-purified lysosomal fractions from Triton-treated rat liver-provide a comprehensive enzymatic mixture that mimics the lysosomal environment. The presented bioanalytical method combines immunoaffinity purification with tritosome-mediated digestion for simultaneous quantitation of dual-conjugated payloads. The method was applied to a model dual-payload ADC containing two different cytotoxic payloads, conjugated using different enzymatically cleavable linkers, with an unrelated DAR (drug-to-antibody ratio). Method validation in mouse plasma demonstrated excellent accuracy (bias ± 20%, LLOQ and ULOQ ± 25%) and precision (coefficient of variation CV% ≤ 20%, LLOQ and ULOQ ± 25%) across all concentration levels (lower to upper limit of quantitation, LLOQ to ULOQ) for both payloads, with 100% of quality control samples (QCs) meeting acceptance criteria for hybrid LC-MS/MS quantitation methods. This tritosome-based approach provides a unified, efficient platform for multi-payload ADC bioanalysis, eliminates linker-specific method optimization, and enables robust support for preclinical studies. The method has been tested for accuracy and precision on 4 different model ADCs and employed to quantify the conjugated payloads in in vivo samples from a homozygous hFcRn transgenic mouse model (Tg32) PK study, resulting in reliable data in accordance with total antibody measurements.

Indexed as

ImmunoconjugatesLiquid Chromatography-Mass SpectrometryAnimalsChromatography, LiquidLiverLysosomesMiceRatsTandem Mass SpectrometryImmunoconjugatesantibody-drug conjugatesbioanalysisconjugated payloaddual-payloadtritosome

Identifiers

PMID42450144
PMCPMC13362250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.